Table 1 |
||||
|
Cohort demographics |
||||
|
RA+aTNF |
RA+MTX |
RA |
Healthy Controls |
|
|
|
||||
|
N |
61 |
70 |
33 |
97 |
|
Age, mean +/- SD years |
55.4 +/- 12.3 |
58.4 +/-12.2 |
57.1 +/-13.8 |
39.8 +/- 13.6 |
|
% female |
82% |
77% |
64% |
63% |
|
Disease duration < 1 year |
5% |
17% |
45% |
NA |
|
Disease duration > 3 years |
93% |
60% |
47% |
NA |
|
Adalimumab n (%) |
9 (15) |
NA |
NA |
NA |
|
Infliximab n (%) |
17 (28) |
NA |
NA |
NA |
|
Etanercept n (%) |
35 (57) |
NA |
NA |
NA |
|
MTX n (%) |
49 (80) |
70 (100) |
0 (0) |
NA |
|
MTX, dose +/- SD mg/wk |
15.2 +/- 4.3 |
16.5 +/- 4.0 |
NA |
NA |
|
corticosteroid n (%) |
18 (29.5) |
26 (37.1) |
10 (30.3) |
NA |
|
corticosteroid, dose +/- SD mg/d |
5.5 +/- 3.5 |
4.9 +/- 2.0 |
10.3 +/-6.1 |
NA |
|
ESR mean (range) |
21 (4-70) |
22 (2-83) |
20 (2-74) |
NA |
|
HAQ mean (range) |
0.71 (0.00-2.22) |
0.73 (0.00-2.75) |
0.46 (0.00-1.63) |
NA |
|
VAS mean (range) cm |
2.8 (0.0-9.8) |
3.3 (0.0-7.5) |
2.8 (0.0-7.1) |
NA |
|
Morning stiffness mean (range) min |
81 (0-780) |
104 (0-1440) |
59 (0-180) |
NA |
|
Race non Caucasian n (%) |
8 (13) |
6 (9) |
2 (6) |
12 (12) |
|
|
||||
|
ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; MTX, methotrexate; NA, not applicable; SD, standard deviation; VAS, visual analogue score. |
||||
|
Kobie et al. Arthritis Research & Therapy 2011 13:R209 doi:10.1186/ar3542 |
||||
